Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

764 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-15

Study Completion Date

2019-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-interventional, retrospective study of advanced SCLC patients in 4 European countries (France, Germany, Italy, and United Kingdom \[UK\]) with the aim to produce evidence across different SCLC treatment lines to characterize the clinical and economic burden of the disease in Europe.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients

NCT03725475

Non-small-cell Lung Cancer (NSCLC)

COMPLETED

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)

NCT03053297

Carcinoma, Non-Small-Cell Lung

TERMINATED

Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment

NCT03419286

Small Cell Lung Cancer

COMPLETED

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

NCT00034957

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

COMPLETED PHASE2

A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil

NCT06008353

Extensive-stage Small-cell Lung Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LD-SCLC receiving 1st line treatment

patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment

No interventions assigned to this group

ED-SCLC receiving 1st line treatment

patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment

No interventions assigned to this group

relapsed/refractory receiving 2nd or later-line treatment

relapsed/refractory patients receiving second- or later-line treatment

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cohort 1 and 2:

* Patients 18 years of age or older at SCLC diagnosis
* Confirmed diagnosis of SCLC within the patient identification period (between October 2013 and October 2015)
* Initiated on first-line treatment (radiotherapy and/or chemotherapy) for their SCLC
* Full oncology medical history for the mandatory variables of the study available in the participating center from day of diagnosis until the end of follow-up or death (whichever occurs first)
* Signed informed consent (where required as per local requirements)

Cohort 3:

* Patients 18 years of age or older at SCLC diagnosis
* Confirmed diagnosis of SCLC not earlier than October 2013
* Initiated on second-line treatment due to relapse after first-line therapy not later than August 2016
* Full oncology medical history for the mandatory variables of the study available in the participating center from day of diagnosis until the end of follow-up or death (whichever occurs first)
* Signed informed consent (where required as per local requirements)

Exclusion Criteria

* Participants with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to first treatment and no additional therapy is required or anticipated to be required during the study period.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No